Cozzolino Mario, Galassi Andrea, Ciceri Paola
Renal Division, ASST Santi Paolo e Carlo, Depart. of Health Sciences, University of Milan, Milan, Italy.
Renal Research Laboratory, Department of Nephrology, Dialysis and Renal Transplant, Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico, Milan, Italy.
Clin Kidney J. 2020 Dec 16;14(2):474-475. doi: 10.1093/ckj/sfaa246. eCollection 2021 Feb.
Patients affected by chronic kidney disease (CKD) have a greater risk of mortality than the general population. Fatal cardiovascular events are the most frequent cause of death in CKD patients, especially in the late stages of disease. Derangement of mineral metabolism and hyperphosphataemia are currently accepted as pivotal triggers of these vascular complications. Phosphate binders represent the common strategy to counteract hyperphosphataemia in dialysis patients. Several studies have reported a reduction in mortality risk in dialysis patients receiving phosphate binders compared with untreated patients, independent of the class of binder prescribed.
慢性肾脏病（CKD）患者的死亡风险高于普通人群。致命性心血管事件是CKD患者最常见的死亡原因，尤其是在疾病晚期。矿物质代谢紊乱和高磷血症目前被认为是这些血管并发症的关键触发因素。磷结合剂是对抗透析患者高磷血症的常用策略。多项研究报告称，与未治疗的患者相比，接受磷结合剂治疗的透析患者死亡风险降低，且与所使用的结合剂类别无关。
